

Supplemental materials

Calcium/Calmodulin Dependent Kinase Kinase 2 (CaMKK2) regulates hematopoietic stem and progenitor cell regeneration

Luigi Racioppi^{1,2^*}, William Lento¹, Wei Huang¹, Stephanie Arvai¹, Phuong L. Doan¹, Jeffrey R Harris¹, Fernando Marcon³, Helder I Nakaya³, Yaping Liu¹, Nelson Chao¹.

Supplemental methods

Pathway analysis

iPathwayGuide® (IPG) software use the impact analysis method with Bonferroni correction. Briefly, this method uses two types of evidence: i) the over-representation of differentially expressed (DE) genes in a given pathway and ii) the perturbation of that pathway computed by propagating the measured expression changes across the pathway topology. These aspects are captured by two independent probability values, pORA and pAcc, that are then combined in a unique pathway-specific p-value. The underlying pathway topologies, comprised of genes and their directional interactions, are obtained from the KEGG database.

RNA isolation and Real-Time PCR

Total RNAs were isolated using QIAquick PCR purification kit (Qiagen, Valencia, CA). Single-stranded cDNA was synthesized using SuperScript II reverse transcriptase (Invitrogen) according to the manufacturer's directions and protocol described previously¹. Real-time PCRs were performed using an iCycler (Bio-Rad) with the IQ SYBR Green supermix (Bio-Rad). After deriving the relative amount of each transcript from a standard curve, transcript levels were normalized to GAPDH. PCR primers were from Qiagen (RT² quantitative PCR primer assays, SABiosciences).

Supplemental Table 1

Top Genes Upregulated in Camkk2 null KSL

| Gene symbol | logfc | adjpv |
|-------------|-------------|----------|
| Cldn13 | -4.59683555 | 0.000001 |
| Ahsp | -4.53838915 | 0.000001 |
| Rhag | -4.40659729 | 0.000001 |
| S100a8 | -4.31267656 | 0.000187 |
| Aqp1 | -3.59649001 | 0.000004 |
| Ces2g | -3.54673969 | 0.000001 |
| Ermap | -3.40552135 | 0.000001 |
| Gm5843 | -3.38201456 | 0.000001 |
| Slc38a5 | -3.28166281 | 0.000001 |
| Klf1 | -3.27487802 | 0.000007 |
| Rhd | -3.27146828 | 0.000005 |
| Nxpe2 | -3.26499576 | 0.000001 |
| Tspan8 | -3.10727365 | 0.000003 |
| Gm15915 | -3.08053288 | 0.000012 |
| Trem3 | -3.06432507 | 0.000005 |
| Fam132a | -3.02237421 | 0.000002 |
| Car1 | -3.01798288 | 0.000001 |
| Ms4a3 | -3.00716665 | 0.000004 |
| Ly6c2 | -2.90853906 | 0.000036 |
| Slc25a21 | -2.86505395 | 0.000001 |
| Atp1b2 | -2.8255369 | 0.000004 |
| Tspan33 | -2.62249231 | 0.000001 |
| Epor | -2.60490944 | 0.000002 |
| Cpox | -2.5525653 | 0.000001 |
| Mt1 | -2.51608227 | 0.000004 |
| Ccne1 | -2.50143595 | 0.000009 |
| Snora73b | -2.49650579 | 0.000067 |
| Ctse | -2.40964417 | 0.011323 |
| Elane | -2.403335 | 0.000012 |
| Paqr9 | -2.403335 | 0.000048 |
| Kel | -2.38508632 | 0.000001 |
| Snora73a | -2.33020026 | 0.000047 |
| Hmbs | -2.30657711 | 0.000001 |
| Asns | -2.29757255 | 0.000001 |
| Ppap2a | -2.10900034 | 0.000001 |
| Gypa | -2.07317193 | 0.000009 |
| Spire1 | -2.02946317 | 0.000002 |

| | | |
|-------|-------------|----------|
| Igsf6 | -2.02814825 | 0.000168 |
| Stom | -2.0255132 | 0.000038 |

Top Genes Downregulated in Camkk2 null KSL

| | | |
|-----------|------------|----------|
| Ighv1-2 | 7.15251158 | 0.000076 |
| Igkv19-93 | 6.08258414 | 0.003751 |
| Dntt | 4.83429581 | 0.000001 |
| Ighm | 4.54881145 | 0.000004 |
| Gm19590 | 4.53270701 | 0.000001 |
| Eltf1 | 3.88341775 | 0.000006 |
| Gcnt2 | 3.74525979 | 0.000004 |
| Igh-VJ558 | 3.65970808 | 0.001526 |
| Ctla2b | 3.60604118 | 0.00001 |
| Gm5111 | 3.57962247 | 0.000001 |
| Igkv4-59 | 3.50735758 | 0.000208 |
| Ighv1-77 | 3.45852245 | 0.000417 |
| Insl6 | 3.41015712 | 0.000006 |
| Flt3 | 3.40585319 | 0.000003 |
| Ctla2a | 3.28053521 | 0.000018 |
| Ighv11-1 | 3.24454357 | 0.000014 |
| Igkv4-54 | 3.15316328 | 0.00007 |
| Igkv4-62 | 3.15230858 | 0.000019 |
| Myct1 | 3.07176696 | 0.000001 |
| Igkv8-30 | 2.98061864 | 0.033687 |
| Gpr56 | 2.97654945 | 0.000008 |
| Igj | 2.95543098 | 0.000546 |
| Igkv4-57 | 2.93916192 | 0.000018 |
| Laptn4b | 2.92477319 | 0.000152 |
| Meis1 | 2.8384935 | 0.000001 |
| Ighv1-73 | 2.83203618 | 0.000539 |
| Ighv1-55 | 2.83085763 | 0.000978 |
| Igkv4-55 | 2.77757626 | 0.000211 |
| Cd34 | 2.74019465 | 0.000002 |
| Igkv4-61 | 2.7304638 | 0.000258 |
| Rbp1 | 2.69665216 | 0.000001 |
| Ighv1-5 | 2.69056489 | 0.0049 |
| H2-Ob | 2.67759099 | 0.000001 |
| Ifi44 | 2.63905733 | 0.003045 |
| Sox4 | 2.61812549 | 0.000001 |
| Tmem176b | 2.61666564 | 0.000001 |


| | | |
|---------------|------------|----------|
| 9030619P08Rik | 2.60786147 | 0.000005 |
| lgkv4-57-1 | 2.60638655 | 0.000214 |
| Angpt1 | 2.60564827 | 0.000001 |

Supplemental Tab 2


Pathway analysis

| pName | pv_bonferroni |
|---|---------------|
| Lysosome | 7.92E-10 |
| Hematopoietic cell lineage | 7.73E-08 |
| Cell adhesion molecules (CAMs) | 8.22E-08 |
| Metabolic pathways | 5.73E-07 |
| Phagosome | 2.08E-05 |
| Natural killer cell mediated cytotoxicity | 6.41E-05 |
| Fc gamma R-mediated phagocytosis | 0.000116349 |
| Antigen processing and presentation | 0.000133403 |
| Pathways in cancer | 0.000158135 |
| Tuberculosis | 0.000437487 |
| Fc epsilon RI signaling pathway | 0.000504321 |
| Leishmaniasis | 0.000580196 |
| Cytokine-cytokine receptor interaction | 0.000777057 |
| Transcriptional misregulation in cancer | 0.000792215 |
| Staphylococcus aureus infection | 0.00098973 |
| FoxO signaling pathway | 0.001262219 |
| Viral myocarditis | 0.001352085 |
| Toxoplasmosis | 0.001699385 |
| Inflammatory bowel disease (IBD) | 0.002013243 |
| Influenza A | 0.002205047 |
| Hepatitis B | 0.002251295 |
| Herpes simplex infection | 0.002351594 |
| Apoptosis | 0.002375065 |
| HTLV-I infection | 0.00267446 |
| Glutathione metabolism | 0.002954605 |
| Type I diabetes mellitus | 0.003012121 |
| Rheumatoid arthritis | 0.003049457 |
| Graft-versus-host disease | 0.003508518 |
| B cell receptor signaling pathway | 0.003607519 |
| Allograft rejection | 0.003775925 |
| T cell receptor signaling pathway | 0.003837721 |
| Jak-STAT signaling pathway | 0.00404303 |
| Osteoclast differentiation | 0.004059177 |
| Leukocyte transendothelial migration | 0.005472502 |
| Chagas disease (American trypanosomiasis) | 0.006290182 |
| Sphingolipid signaling pathway | 0.008017898 |

| | |
|--|-------------|
| Viral carcinogenesis | 0.011033526 |
| Measles | 0.012717421 |
| Central carbon metabolism in cancer | 0.013339102 |
| Ras signaling pathway | 0.017951374 |
| Systemic lupus erythematosus | 0.020248129 |
| ABC transporters | 0.021274373 |
| MAPK signaling pathway | 0.021903743 |
| Chemokine signaling pathway | 0.027561406 |
| Intestinal immune network for IgA production | 0.036701637 |




Supplemental Figure S1. Camkk2 differentially modulate stem cell- and lineage-associated transcriptional programs. Heatmap representation showing differentially expressed genes in: (A) hematopoietic stem cells; (B) immediate downstream progenitors; (C) lineage-affiliated genes in Camkk2 KO compared to WT KSL. Genes in bold red text are reported to induce reprogramming of differentiated hematopoietic cells into induced HSCs. The color key for all heatmaps indicates row-wise scaled RPKM values (z-score).




Venezia et al. *Plos Biology* 2004


Supplemental Figure S2. Genes affiliated with hematopoietic stem cell quiescence are down regulated in *Camkk2* null KSL. (A) Venn diagram showing the overlapping of genes down or up regulated in *Camkk2* null KSL compared to WT (KO DN and KO UP, respectively) with genes affiliated with quiescent or proliferating hematopoietic stem cells (HQ-Sign and HP-Sign, respectively). (B) Genes affiliated with hematopoietic stem cell quiescent signature are significantly downregulated in *Camkk2* null KSL ($p = 0,0001$). (C) Loss of *Camkk2* downregulates the genetic quiescent signature in stem cells. Fold chance of HQ-Sign genes significantly downregulated in *Camkk2* null KSL compared to WT genes. Venny 2.0² was used for Venn diagram analyses.




Supplemental Figure S3. Camkk2 null mice have improved survival and accelerated hematopoietic recovery following total body irradiation. Mice were TBI and monitored for survival and blood cell count recovery. (A) Survival of WT and Camkk2 null mice (WT and KO, respectively) irradiated with 800cGy (n = 13 mice/genotype). Cell blood count number in WT and KO mice TBI with 700 cGy and monitored by CBC (n = 6 and 9 for WT and KO group, respectively). The absolute numbers +/- SEM are shown. Bars graphs show pre-TBI CBC. *p<0.05, **p<0.01, ***p<0.005. **** p<0.001.




Supplemental Figure S4. Camkk2 null mice have an accelerated bone marrow recovery following total body irradiation. WT and KO mice were irradiated with 700cGy TBI and sacrificed on day 14. (A) Representative hematoxylin and eosin staining of WT and Camkk2 null mice (WT and KO, respectively) femur sections. (B) Absolute count number of white BM cells (WBMC) isolated from femurs of non-irradiated and TBI mice (left and right bar graphs, respectively; n = 10 mice/group). Data refers to cells recovered from one bone. (C) Gating strategy to identify SLAM KSL cells. Percentage of SLAM KSL in non-irradiated and TBI WT and KO mice (D and E panels, respectively; n = 6 mice/genotype). Bars graph reports mean +/- SEM. * p-values < 0.05; ** p-values < 0.01.




Supplemental Figure S5. Effect of genetic ablation of *Camkk2* on HSPC survival under homeostatic conditions and following total body irradiation. (A) gating strategy to identify KL and KSL live and death cells by using Annexin-V and 7AAD in bone marrow of non-irradiated WT and *Camkk2* null mice (WT and KO, respectively). (B) Percentages of live KSL and KL cells in non-irradiated WT and *Camkk2* null mice (n = 6 mice/genotype). (C) WT and KO mice were euthanized 24-hours after 450cGy TBI and apoptotic and live KL and KSL cells were identified by flow cytometry. (D) The percentage of Annexin V-/7AAD- live cells in irradiated WT and KO mice is shown (n = 6/genotype). Bars graph reports mean +/- SEM. * p-values < 0.05.



Supplemental Figure S6. Loss of Camk2 does not impair the engraftment potential of irradiated hematopoietic stem cells. Control and Camk2 null mice received 200cGy TBI and were allowed to regenerate. KSLCD34⁻ cells were then sorted from the irradiated donors and transplanted into lethally irradiated recipient mice with competitor bone marrow. The recipient mice were bled at 8 weeks and donor CD45.2 chimerism was analyzed by flow cytometry. There was no significant difference in peripheral blood chimerism at 8 weeks. The data indicate the accelerated regeneration found in irradiated Camk2 null HSCs is not associated with decreased transplantation function or malignant transformation. Bars graph reports mean +/- SD; n = 6 mice/group).



Supplemental Figure S7. *Camkk2* null HSCs have a cell-intrinsic enhanced regenerative capability *in vivo*. KSLCD34⁻ cells were isolated from WT and KO and transplanted in lethally irradiated recipient mice with CD45.1 competitor bone marrow. The recipient mice receiving WT or KO KSLCD34⁻ cells were monitored for 4 months. Subsequently, mice showing comparable percentages of WT or KO donor's CD45.2 cells were irradiated with 450cGy TBI and bled weekly after irradiation. Donor CD45.2 chimerism was monitored by flow cytometry and the results expressed as fold change over the basal level (pre-TBI). (A) Scheme of the experiment. (B) CD45.2 chimerism in mice reconstituted with WT or KO KSLCD34⁻ before TBI. (C) Kinetics of CD45.2 chimerism. Blue and red dotted lines indicate CD45.2 chimerism in individual mice transplanted with WT or KO KSLCD34⁻ cells, respectively. Blue and red bold lines indicate the average of CD45.2 fold change in WT and KO group, respectively (n= 6 mice /group). Bars graph reports mean +/- SEM. * p<0.05, ** p<0.01, *** p<0.05.



Supplemental Figure S8. Modeling CaMKK2 deficiency in the myeloblastic M1 cell line. M1 cells were transduced with a lentiviral vector or expressing a control sequence or a short hairpin sequence for silencing Camk2 (Ctrl and ShCamk2, respectively). (A) Normalized Camk2 mRNA expression in M1 cells transduced with control or ShCamk2 vectors (left; n = 6). Camk2 gene expression in fresh isolated WT and Camk2 null (KO) KSL (right; n = 9). (B) Normalized gene expression in transduced M1 cells and primary WT and KO KSL. The selected genes were highly expressed in both cell types (M1 and KSL), and differentially expressed (DEGs) KO KSL compared to WT. Silencing of Camk2 in M1 cells and Genetic ablation of CaMKK2 has similar effects on gene expression. Bars graph reports mean +/- SEM. * p<0.05, ** p<0.01, *** p<0.05, **** p<0.05.

References

- 1 Racioppi, L., Noeldner, P. K., Lin, F., Arvai, S. & Means, A. R. Calcium/calmodulin-dependent protein kinase kinase 2 regulates macrophage-mediated inflammatory responses. *J Biol Chem* **287**, 11579-11591, doi:10.1074/jbc.M111.336032 (2012).
- 2 Oliveros, J. C. Venny. An interactive tool for comparing lists with Venn's diagrams., <<http://bioinfogp.cnb.csic.es/tools/venny/index.html>> (2007-2015).